Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24758311 | 1.00 | MAOA (0.65) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL24756833 | 0.94 | MAOA (0.67) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL31346495 | 0.92 | MAOA (0.55) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL14303568 | 0.91 | MAOA (0.66) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL29933810 | 0.90 | MAOA (0.65) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL18800809 | 0.90 | MAOA (0.65) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL4744257 | 0.88 | MAOA (0.69) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL4744259 | 0.88 | MAOA (0.69) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL4740874 | 0.86 | MAOA (0.66) | MAOAGAAMGAMSIPTPN1 | |
| SCHEMBL24756232 | 0.86 | MAOA (0.66) | MAOAGAAMGAMSIPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025048007-A1 | COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE, CONTAINING NOVEL COMPOUND | (주)피알지에스앤텍 | 2025-03-06 | — | — | WO | claimed |
| WO-2025023339-A1 | COMPOSITION CONTAINING NOVEL COMPOUND FOR PREVENTING OR TREATING PARKINSON'S DISEASE | (주)피알지에스앤텍 | 2025-01-30 | — | — | WO | claimed |
| EP-4056573-B1 | USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | PRG S&TECH INC (KR) | 2024-11-06 | — | — | EP | claimed |
| US-20220402930-A1 | USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | PRG S&TECH INC. (KR) | 2022-12-22 | — | — | US | claimed |
| EP-4056573-A1 | USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | PRG S&Tech Inc. (KR) | 2022-09-14 | — | — | EP | claimed |
| WO-2025048007-A1 | COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE, CONTAINING NOVEL COMPOUND | (주)피알지에스앤텍 | 2025-03-06 | — | — | WO | disclosed |
| WO-2025023339-A1 | COMPOSITION CONTAINING NOVEL COMPOUND FOR PREVENTING OR TREATING PARKINSON'S DISEASE | (주)피알지에스앤텍 | 2025-01-30 | — | — | WO | disclosed |
| EP-4056573-B1 | USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | PRG S&TECH INC (KR) | 2024-11-06 | — | — | EP | disclosed |
| US-20220402930-A1 | USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | PRG S&TECH INC. (KR) | 2022-12-22 | — | — | US | disclosed |
| EP-4056573-A1 | USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | PRG S&Tech Inc. (KR) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402930-A1 | USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SOD1, SLC75A1, SLC43A1 | MAOA 2110/4885GAA 1104/4885MGAM 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.